Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Sam Citron who wrote (14880)	12/22/2004 2:06:37 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 52153

If you used this thread, and others at S.I., as an information source/base rather than whatever the hell it is that you do (screech, whine, charge!?), you'd have known it as well. Many at S.I. have surveyed the medical literature and industry rags for years. We share information, here. Topol is outraged? Wow, news. FDA needs more money for post-market surveillance? Wow, news. Vioxx had pending issues re. risk/benefit, given that it was prescribed for chronic diseases and that an alternative was available? Wow, news. Not. Some SI biofreaks from early years have long ago moved on to industry positions from graduate work or postdocs. Some have moved from those positions to senior management slots. Some of the original gang, senior managers, are still contributing. Etc., etc. All of this stuff is new to you, but it's all splayed out here at S.I. and in trade publications. You just have no respect for the forum in which you participate, and it continues to show.